Lupin Ltd has announced that the Company had in February 2006 signed an MOU with Aspen Pharmacare Holdings Ltd., South Africa for a 50:50 Joint Venture for the development, manufacture and global marketing (except US, South Africa & India Trade) of a range of Anti-TB products.
Based on subsequent discussions, both the parties have mutually agreed not to pursue the said MOU. However, they would continue to collaborate for TB related products market in the Republic of South Africa as per the agreement entered in September 2005.